i) hydrogen,

ii) halo-C_{1-6}alkyl, and

iii) halogen;,

or a pharmaceutically acceptable salt thereof.

16. The process according to claim 15, wherein R^1 is cyano.

17. The process according to any of claims 15-16, wherein R^3 is F.

18. The process according to any of claims 15-17, wherein R^4 is C_{1-6}alkyl.

19. The process according to any of claims 15-18, wherein R^4 is methyl.

20. The process according to any of claims 15-19, wherein R^5 and R^6 are both hydrogen.

21. The process according to any of claims 15-19, wherein R^5 and R^6 are both halogen.

22. The process according to claim 21, wherein R^5 and R^6 are both fluoro.

23. The process according to any of claims 15-22, wherein R^7 and R^8 are both hydrogen.

24. The process according to any of claims 15-22, wherein R^7 and R^8 are both halogen.

25. The process according to claim 24, wherein R^7 and R^8 are both fluoro.

26. The process according to any of claims 15-26, wherein X is –CH.

27. A compound of formula I, whenever synthesized via a carbonylation as described in any of claims 1-14.

28. A compound of formula VI, synthesized via a process as described in any of claims 15-16.

29. A compound of formula VI according to claim 28 for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated β-amyloid levels and/or β-amyloid oligomers and/or β-amyloid plaques and further deposits, particularly Alzheimer's disease.

30. A pharmaceutical composition comprising a compound of formula VI according to claim 28 and a pharmaceutical acceptable carrier and/or a pharmaceutical acceptable auxiliary substance.

~~31. The invention as described hereinabove.~~